EHA 2021 | Key updates on MPNs from EHA 2021
Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX, gives an overview of the current state-of-the art therapies for the treatment of myeloproliferative neoplasms (MPNs) presented at EHA 2021. Dr Pemmaraju highlights three major developments; the large number of Phase III randomized trials, add-on combination strategies, and developments in the treatment of polycythemia vera. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Naveen Pemmaraju, MD, is a member of the ASH Communications Committee and the ASCO Leukemia Advisory panel; has participated in consultancy work for Pacylex Pharmaceuticals, ImmuniGen, Bristol Myers Squibb, Blueprint Medicines, Clearview Healthcare Partners, Astellas Pharma US Inc., Triptych Health Partners and CTI Biopharma; has received grants from Affymetrix and SagerStrong Foundation; has received honoraria from Incyte, Novartis, LFB Biotechnologies, Stemline Therapeutics, Celgene, AbbVie, MustangBio, Roche Diagnostics, Blueprint Medicines, DAVA Oncology, Springer Science + Business Media LLC, Aptitude Health, NeoPharm Israel and CareDx, Inc., has received research support from Novartis, Stemline Therapeutics, Samus Therapeutics, AbbVie, Cellectis, Affymetrix, Daiichi Sankyo and Plexxikon; and has received travel reimbursement from Stemline Therapeutics, Celgene, MustangBio, DAVA Oncology and AbbVie.
